DENVER – Revelation Pharma, a portfolio company of Osceola Capital, announced Thursday that it has completed the acquisitions of five compounding pharmacies, to include: Innovation Compounding, Pencol Compounding Pharmacy, Pharmacy Specialists Compounding, Wise Compounding, and Convex Pharmacy. In 2021, Osceola formed Revelation Pharma with the acquisition of Everwell Specialty Pharmacy.

Innovation Compounding, headquartered in Kennesaw, Ga., provides custom compounded medications for patients and physicians nationwide. Innovation specializes in men and women’s health, allergy and nutrition therapy, pain management, and dermatology. Visitwww.innovationcompounding.com to learn more.

 Pencol Compounding, headquartered in Denver, Colo., provides custom compounded medications for patients and physicians in Colorado and the Mountain West. Pencol specializes in men and women’s health, veterinary products, pain management, and dermatology. Visit www.pencolpharmacy.com to learn more.

Pharmacy Specialists Compounding, headquartered in Altamonte Springs, Fla., provides custom compounded medications for patients and physicians throughout Florida and surrounding states. Pharmacy Specialists specializes in men and women’s health, immune system and thyroid therapy, and pain management. Visit www.makerx.com to learn more.

 Wise Pharmacy, headquartered in Littleton, Colo., provides custom compounded medications for patients and physicians throughout Colorado and will be merged with Pencol Compounding

 Convex Pharmacy, headquartered in Orland Park, Ill., provides custom compounded medications for patients and physicians nationwide and will be merged with Everwell Specialty Pharmacy.

 “We’re excited to welcome Innovation, Pencol, Pharmacy Specialists, Wise and Convex to the Revelation platform. These partnerships add to our expertise in a wide variety of innovative therapies, and we remain focused on looking for new acquisitions to expand our capabilities and better serve our customers,” said Jake Beckel, chairman of Revelation Pharma.

 Ben Moe, managing partner of Osceola Capital, adds, “These acquisitions are highly strategic to the Revelation platform – expanding our geographic reach to key areas of the US and adding talented leadership to the business. We look forward to continuing an aggressive acquisition growth strategy and partnering with best-in-class compounding pharmacies nationwide.”